Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial

Donald L. Morton, John F. Thompson, Richard Essner, Robert Elashoff, Stacey L. Stern, Omgo E. Nieweg, Daniel F. Roses, Constantine P. Karakousis, Nicola Mozzillo, Douglas Reintgen, He Jing Wang, Edwin C. Glass, Alistair J. Cochran

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate the multicenter application of intraoperative lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection (LM/SL/SCLND) for the management of early-stage melanoma. Summary Background Data: The multidisciplinary technique of LM/SL/SCLND has been widely adopted, but not validated in a multicenter trial. The authors began the international Multicenter Selective Lymphadenectomy Trial (MSLT) 5 years ago to evaluate the survival of patients with early-stage primary melanoma after wide excision alone versus wide excision plus LM/SL/SCLND. This study examined the accuracy of LM/SL/SCLND in the MSLT, using the experience of the organizing center (John Wayne Cancer Institute [JWCI]) as a standard for comparison. Methods: Before entering patients into the randomization phase, each center in the MSLT was required to finish a 30-case learning phase with complete nuclear medicine, pathology, and surgical review. Selection of MSLT patients in the LM/SL/SCLND treatment arm was based on complete pathologic and surgical data. The comparison group of JWCI patients was selected using these criteria: primary cutaneous melanoma having a thickness ≥1 mm with a Clark level ≥III, or a thickness

Original languageEnglish
Pages (from-to)453-465
Number of pages13
JournalAnnals of Surgery
Volume230
Issue number4
DOIs
Publication statusPublished - Oct 1999

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial'. Together they form a unique fingerprint.

Cite this